The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...
Shares of BioArctic AB (STO:BIOA B) climbed 4.8% following the announcement of its partner Eisai's robust sales figures for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback